Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Receivables (2017 - 2020)

Cogent Biosciences has reported Change in Receivables over the past 4 years, most recently at -$2.0 million for Q1 2020.

  • Quarterly results put Change in Receivables at -$2.0 million for Q1 2020, down 637.63% from a year ago — trailing twelve months through Dec 2020 was -$2.0 million (down 702.41% YoY), and the annual figure for FY2020 was -$2.0 million, down 702.41%.
  • Change in Receivables for Q1 2020 was -$2.0 million at Cogent Biosciences, down from $1.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for COGT hit a ceiling of $1.1 million in Q4 2019 and a floor of -$2.0 million in Q1 2020.
  • Median Change in Receivables over the past 4 years was $217000.0 (2018), compared with a mean of -$71384.6.
  • Biggest five-year swings in Change in Receivables: soared 1980.49% in 2018 and later plummeted 637.63% in 2020.
  • Cogent Biosciences' Change in Receivables stood at -$681000.0 in 2017, then skyrocketed by 136.56% to $249000.0 in 2018, then skyrocketed by 349.8% to $1.1 million in 2019, then plummeted by 278.57% to -$2.0 million in 2020.
  • The last three reported values for Change in Receivables were -$2.0 million (Q1 2020), $1.1 million (Q4 2019), and -$612000.0 (Q3 2019) per Business Quant data.